A71623

A71623, a CCK-4-based peptide, is a potent and highly selective CCK-A full agonist. The IC50s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively[1].

Product Specifications

CAS Number

[130408-77-4]

UNSPSC

12352209

Target

Cholecystokinin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/a71623.html

Purity

99.34

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(N[C@@H](CCCCNC(NC(C=CC=C1)=C1C)=O)C(N[C@@H](CC(O)=O)C(N(C)[C@H](C(N)=O)CC2=CC=CC=C2)=O)=O)[C@@H](NC(OC(C)(C)C)=O)CC3=CNC4=CC=CC=C34

Molecular Formula

C44H56N8O9

Molecular Weight

840.96

References & Citations

[1]C W Lin, et al. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol. 1991 Mar;39 (3) :346-51.|[2]K E Asin, et al. Effects of selective CCK receptor agonists on food intake after central or peripheral administration in rats. Brain Res. 1992 Jan 31;571 (1) :169-74.|[3]Emily A.L. Wozniak, et al. Cholecystokinin 1 Receptor (Cck1R) Activates mTORC1 signaling and is Protective to Purkinje cells in SCA Mice. bioRxiv. February 17, 2021.